Inactive Instrument

AVITA Medical, Inc. Stock Other OTC

Equities

AVHHL

AU000000AVH4

Biotechnology & Medical Research

Financials

Sales 2024 * 113M 75.72M 103M Sales 2025 * 158M 105M 144M Capitalization 356M 238M 324M
Net income 2024 * -66M -44.08M -60.11M Net income 2025 * -32M -21.37M -29.15M EV / Sales 2024 * 2.77 x
Net cash position 2024 * 41.66M 27.82M 37.95M Net Debt 2025 * 1.53M 1.02M 1.39M EV / Sales 2025 * 2.27 x
P/E ratio 2024 *
-5.24 x
P/E ratio 2025 *
-11.8 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.3%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on AVITA Medical, Inc.

AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
Calendar
Related indices
More about the company